At Vanqua, we’re taking a patient-focused approach to develop next-generation drugs for neurodegeneration. In an episode of Biomarker podcast, Vanqua CEO Jim Sullivan and host @dylanvneel dive into our science: https://t.co/3ZMUhSUkId #Biopharma

Our Chief Medical Officer Maurizio Facheris joined industry experts for @MichaelJFoxOrg online panel, “Year of Momentum: What Parkinson's Research Accomplished in 2024.” Listen to a recording here: https://t.co/nUDeCdFNDY

Kevin Hunt, Vanqua’s CSO, will present at the 8th Complement-Based Drug Development Summit on Dec. 12 at 12 PM ET. He will share pre-clinical data on our development candidate VQ-201 and cover the first-in-class CNS-penetrant C5aR1 antagonists. Learn more: https://t.co/UqWQkfdI1F

We recently celebrated our five-year anniversary. Many thanks to our team whose passion and commitment empower our work every day. We look forward to many more years of innovation, achievement, and growth.

We were pleased to attend @MichaelJFoxOrg’s Parkinson’s Disease Therapeutics Conference and connect with fellow leaders committed to developing effective therapies for #ParkinsonsDisease.

A warm welcome to Maurizio Facheris, M.D. who joined Vanqua Bio as Chief Medical Officer. His experience of advancing #ParkinsonsDisease therapies will be instrumental to the advancement of VQ-101. https://t.co/P5lmoa9GIC

We are pleased to share positive interim results from our Phase 1 clinical trial of VQ-101 for the treatment of GBA-Parkinson’s and related disorders conducted at @CHDR_NL. https://t.co/P5lmoa9GIC

Vanqua Bio will participate in two upcoming scientific conferences: Grand Challenges in Parkinson’s Disease Symposium and #MDSCongress. For details, read the full press release here: https://t.co/DHs4cNSKBO #ParkinsonsDisease

On #WorldBrainDay, we join the neurological community to raise awareness of brain health. We remain committed to discovering innovative therapies capable of effectively slowing or halting the progression of neurodegenerative disorders, including #ParkinsonsDisease.

We look forward to the inaugural GBA1 meeting hosted by @TheNeuro_MNI, bringing together health professionals in #GBA1 research. As a presenter and a sponsor, we look forward to discussions on GBA1-associated neurodegenerative diseases. Learn more: https://t.co/E0QnvWwN5E

We are pleased to welcome Hunter Smith to our Board of Directors. With 30+ years in global finance, Hunter brings a wealth of expertise and strategic vision to our team. Hunter’s experience will be critical as we progress our evolution as a clinical-stage company.

Our team had a great time at @MichaelJFoxOrg Chicago Run/Walk this past Sunday. This is an important event in support of the future without #Parkinsons. #RunWalk #Chicago

Lace up your sneakers and join us in the fight against #ParkinsonsDisease. By participating in @MichaelJFoxOrg Chicago Run/Walk, you're helping make strides towards a cure. Register now! We look forward to seeing you there: https://t.co/3ddKbyeeYK #OutrunPD

April 27th marks the 30th annual Parkinson's Unity Walk in NYC's Central Park hosted by @MichaelJFoxOrg! Let's unite to end Parkinson's disease together. Register now to be part of this milestone event. https://t.co/Ho7yx3abjc #UnityWalk #ParkinsonsAwareness

At Vanqua Bio, we're dedicated to discovering and delivering next-generation medicines for diseases such as #Parkinsons. Join us this #WorldParkinsonsDay in raising awareness and hope for those impacted. Together, we can make strides towards a brighter future.#ParkinsonsAwareness

We're pleased to announce the first patient has been dosed in Phase 1 clinical study for VQ-101, a novel GCase activator for the treatment of GBA #ParkinsonsDisease. To learn more, read our press release: https://t.co/CMxw6P9Pxh #clinicaltrials

Our CEO Jim Sullivan, PhD, will present at the Stifel 2024 CNS Days Conference on Tuesday, March 19, 4-4:25 p.m. ET. To learn more, visit: https://t.co/1ZQmmI2mar #neuroscience

We will be presenting pre-clinical data on VQ-101, our clinical stage GCase activator for the treatment of GBA‐associated #Parkinsons at #ADPD2024. For further info, visit: https://t.co/B06JjmTlrm

#ICYMI we advanced our development candidate, VQ-101, for the treatment of #ParkinsonsDisease due to mutations in GBA1, the gene that encodes glucocerebrosidase (GCase). https://t.co/gMgP1mjphs

We are proud to announce Rand Sutherland, MD, MPH as the new member of our Board of Directors. Rand is a physician-scientist focused on developing #noveltreatments for patients with rare and difficult-to-treat conditions across multiple therapeutic areas. https://t.co/gMgP1mjX70

We are pleased to welcome Omer Siddiqui to Vanqua Bio as our new Chief Development Officer! We look forward to working together as we advance our development candidates into clinical studies. https://t.co/gMgP1mjX70